AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01942993
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
Trial: NCT00293436
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02047097
Drug: dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provided under routine clinical care
Trial: NCT03233152
Drug: Ipilimumab (YervoyTM, 50 mg/10 mL solution)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec.
Trial: NCT03233152
Drug: Nivolumab (OpdivoTM, 40 mg/4mL solution)
RxNorm normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
Trial: NCT03624283
Drug: Betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine is used in the treatment of and vertigo.
Trial: NCT01002742
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Trial: NCT02035800
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will received medication as standard of care
Trial: NCT00450073
Drug: ergocalciferol (vitamin D2)
RxNorm normalized name: ergocalciferol (vitamin D2)
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50,000 IU weekly
Trial: NCT00450073
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU weekly
Trial: NCT06066073
Drug: Lavender Oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
Trial: NCT06066073
Drug: Distal Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
Trial: NCT02131272
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
Trial: NCT01545583
Drug: LY3016859 intravenous
RxNorm normalized name: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
DrugBank: Fepixnebart (DB19079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT02209974
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
Trial: NCT04474626
Drug: Isoquercetin
RxNorm normalized name: Isoquercetin
DrugBank: Isoquercetin (DB12665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
Trial: NCT01545583
Drug: LY3016859 subcutaneous
RxNorm normalized name: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
DrugBank: Fepixnebart (DB19079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT02142309
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
Trial: NCT02142309
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
Trial: NCT02142309
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start with 15 mg/day and advance to 30 mg/day
Trial: NCT02142309
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
Trial: NCT01998919
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
Trial: NCT01922115
Drug: Trospium Chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
Trial: NCT01925950
Drug: orBec
RxNorm normalized name: {200 (beclomethasone dipropionate 1 MG Delayed Release Oral Tablet) / 200 (beclomethasone dipropionate 1 MG Oral Tablet) } Pack [orBec]
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02450331
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered at a dose of 1200 milligrams (mg).
Trial: NCT00373399
Drug: Inactive Marijuana (0% THC)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Trial: NCT02263105
Drug: CDDP
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01998919
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
Trial: NCT02263105
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
Trial: NCT00373399
Drug: Low THC marijuana (1.8 %THC)
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Trial: NCT00373399
Drug: High THC marijuana (3.9% THC)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Trial: NCT04186377
Drug: S26E
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily application of S26E extract on wound site
Trial: NCT00529009
Drug: UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01998919
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
Trial: NCT00042679
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00042679
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01998919
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Trial: NCT02643732
Drug: Methylphenidate (overencapsulated)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Trial: NCT03696901
Drug: Xydalba
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Trial: NCT04190004
Drug: Vasopressins
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Trial: NCT01423916
Drug: OPC-34712 (4mg)
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention receive 4mg.
Trial: NCT01423916
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive 400mg.
Trial: NCT01423916
Drug: OPC-34712 (12mg)
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention receive 12mg.
Trial: NCT02976441
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01020097
Drug: fluorine F18 EF5
RxNorm normalized name: fluorine
DrugBank: Fluorine F-18 (DB13134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01471210
Drug: Urelumab (BMS-663513)
RxNorm normalized name: Avelumab
DrugBank: Urelumab (DB12077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04378231
Drug: Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dry suspension of amoxicillin clavulanate potassium
Trial: NCT00652886
Drug: Oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10mg, single-dose
Trial: NCT00652886
Drug: Oxandrin
RxNorm normalized name: Oxandrin
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 10mg, single-dose
Trial: NCT03313336
Drug: EMLA current reference patch
RxNorm normalized name: lidocaine / prilocaine Medicated Patch [EMLA]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
Trial: NCT03695822
Drug: Mirabegron 25mg
RxNorm normalized name: MIRABEGRON 25MG SA TAB
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Trial: NCT00518297
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, Oral, 400 mg, twice daily for 5 Days
Trial: NCT00518297
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 300 mg, twice daily for 7 Days
Trial: NCT00518297
Drug: Atazanavir + Raltegravir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
Trial: NCT01088022
Drug: Aprepitant, Palonosetron, Dexamethasone
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Trial: NCT01088022
Drug: Placebo, Palonosetron, Dexamethasone
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Trial: NCT01079936
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
Trial: NCT01079936
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
Trial: NCT00624754
Drug: Formoterol/Budesonide
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
Trial: NCT02522650
Drug: Triamterene
RxNorm normalized name: Triamterene
DrugBank: Triamterene (DB00384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg twice a day for 8 weeks
Trial: NCT01992380
Drug: Flortaucipir F18
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
Trial: NCT05418036
Drug: Sotalol Oral Tablet
RxNorm normalized name: sotalol Oral Tablet
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
Trial: NCT00626028
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
Trial: NCT03827668
Drug: PF-06650833 alone
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
Trial: NCT03827668
Drug: PF-06651600 alone
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
Trial: NCT03827668
Drug: PF-06650833 together with PF-06651600
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
Trial: NCT01353144
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin, 100 mg, qd x 8 weeks
Trial: NCT00831779
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 5 mg, once daily, 12 weeks
Trial: NCT00712868
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day
Trial: NCT01109693
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/d or 100 mg/d for 6 more weeks
Trial: NCT01109693
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Augment with or switch to mirtazapine 15-45 mg/d
Trial: NCT01156779
Drug: SR-exenatide
RxNorm normalized name: Peg loxenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
Trial: NCT01302743
Drug: Group 1: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
Trial: NCT01416870
Drug: Casodex 80 mg tablet
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will receive single dose of Casodex 80 mg tablet
Trial: NCT01602887
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: isethionate hard capsule, 125 mg, single dose
Trial: NCT01602887
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: freebase hard capsule with a small particle size, 125 mg, single dose
Trial: NCT01602887
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: freebase hard capsule with a large particle size, 125 mg, single dose
Trial: NCT01602887
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral solution, 50 mg, single dose
Trial: NCT00696748
Drug: Nebido (testosterone undecanoate)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
Trial: NCT02506842
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Trial: NCT02506842
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
Trial: NCT02506842
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
Trial: NCT02506842
Drug: folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Trial: NCT01982240
Drug: Plecanatide
RxNorm normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plecanatide tablets QD for 12 weeks
Trial: NCT01982240
Drug: Bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rescue medication